Breast Cancer, Cervical Cancer, Cholangiocarcinoma, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Thyroid Cancer
Conditions
Brief summary
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. The goal is to construct a plasma metabolite database for multi-cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early multi-cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of multi-cancer.
Detailed description
Firstly, a wide-targeted metabolomic measurement will be conducted on all samples to identify potential metabolite candidate markers and analyze differences in the metabolic profiles of patients with different types of cancer. Additionally, a comprehensive metabolite database specific to cancer patients will be constructed. Secondly, Samples will be randomly allocated into modeling and testing cohorts. The modeling cohort will be further divided into training and validation sets. Bioinformatics methods will be used to conduct an in-depth analysis of a wide range of metabolite information to screen out metabolic marker combinations with high diagnostic efficacy for cancer. Ultimately, the testing cohort will be used to validate these metabolic biomarkers, aiming to ensure reliability and stability across different patient populations.
Interventions
None listed
Sponsors
Beijing Friendship Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Multi-Cancer Group: * Patients with a confirmed diagnosis based on the clinical gold standard. * Collection of plasma samples prior to treatment. * Availability of complete clinical data. * Control Group: * Individuals with no abnormalities in routine physical examinations and relevant clinical tests. * Age ≥ 45 years. * Availability of complete clinical data.
Exclusion criteria
* Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. * Coexistence of other systemic tumors. * Absence of plasma sample collection before treatment. * Pregnancy status. * No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion). * Patients with severe acute infections. * Patients with severe anemia. * Patients with severe liver or kidney dysfunction. * Patients with autoimmune deficiency diseases. * Patients with Hyperlipidemia. * Patients received contrast agent injection before blood draw. * Patients with psychiatric disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma metabolite content | Before receiving treatment for cancer | The outcome will be tested by metabolomics detection technology based on mass spectrometry |
Countries
China
Contacts
Primary ContactLi Min, Ph.D.
Backup ContactBilian Kang, Ph.D.
Outcome results
None listed